Natural history of macrovascular disease and classic risk factors for atherosclerosis

Diabetes Care

Volumn 22, Issue SUPPL. 3, 1999, Pages

  Eckel, Robert H ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETIC OBESITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPOINSULINEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 0032913070     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300-304, 1989
2. Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990
3. McGill HC, McMahan A, Malcolm GT, Oalmann MC, Strong JP, the Pathobiological Determinants of Atherosclerosis in Youth the interplay between insulin secretion and sensitivity as determinants of glucose intolerance. Acta Diabetologica 31:26-30, 1994
4. Breyer JA: Therapeutic interventions for nephropathy in type 1 diabetes mellitus. Semin Nephrol 17:114-123, 1997
5. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, Ujihara U, Takahashi C, Omori Y: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40:405-411, 1997
6. Makino N, Sugano M, Otsuka S, Hata T: Molecular mechanism of angiotensin 11 type 1 and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 30:796-802, 1997
7. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14. JAMA 268:1292-1300, 1992
8. Yudkin JS: How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 306:1313-1318, 1993 [published errata appear in BMJ 306:1739, 1993 and 307:1161, 1993]
9. Pyorala K, Pedersen TR Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
10. Goldberg RB, Mellics MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MP, Braunwald E, for the CARE Investigators: Cardiovascular events and their reduction with provastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 98:2513-2519, 1998
11. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 21:179-182, 1998
12. Steiner G: The Diabetes Atherosclerosis Intervention Study (DAIS), a study conducted in cooperation with the World Health Organization. Diabetologia 39:1655-1661, 1996
13. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998